On this page, we anticipate important topics that will be included in the next COVID Reference edition. Some of the information presented here may not derive from peer-reviewed papers but could have an impact on treatment and on our current understanding of COVID-19.
Kawasaki-like syndrome in children – A new twist in this new pandemic: at the end of March 2020, Jones et al. described the case of a six-month-old baby girl with fever, rash and swelling characteristic of a rare pediatric inflammatory condition, Kawasaki syndrome (Jones 2020). >>> Read more
Top 10 Special on Remdesivir
Get it done! – On remdesivir, rumors of recovery, rolling reviews, and random noise
“That’s very exciting. Get it done, Daniel.” If you want to get an idea about the incredible pressure on and expectations from researchers, then please read the protocol from the White House (Trump 2020). NIAID’s Anthony Fauci and Gilead’s CEO Daniel O’Day make heroic attempts to explain the situation to decision makers. This pressure has its consequences. >>> Read more
Top Ten Special on
There has hardly been a topic in the last weeks of this pandemic that has kept doctors (mainly internists) and their patients as busy as the question of whether ACE inhibitors or angiotensin-receptor blockers (ARBs) can cause harm to patients. Early observations of an increased risk for mortality or severe COVID-19 in patients with hypertension, cardiovascular diseases and diabetes (Guan 2020) raised concerns. >>> Read more
Remdesivir (abbreviation: RDV) is a monophosphoramidate prodrug of an adenosine analog with potent activity against an array of single stranded RNA virus families including Filoviridae, Paramyxoviridae, Pneumoviridae, and Orthocoronavirinae (Brown 2019, Sheehan 2017), through the targeting of the viral RNA dependent RNA polymerase (RdRp) (Cho 2012, Agostini 2018).
Press release – Sanofi and Regeneron provide an update on U.S. Phase 2/3 adaptive-designed trial in hospitalized COVID-19 patients.
Breaking news from Sanofi on immunotherapies. Preliminary data of sarulimab (Kevzara®), a monoclonal antibody against the IL-6 receptor, raise the question of whether IL-6 blockers can be harmful in COVID-19. After reviewing 457 hospitalized patients, an Independent Data Monitoring Committee recommended continuing ongoing Phase II/III trial only in the more advanced “critical” group and discontinuing the trial in the less advanced “severe” group. For severe patients (no mechanical or high-flow oxygenation), negative trends with sarulimab were seen, particularly with the lower 200 mg dose. However, in critically ill patients, exploratory clinical endpoints showed some (minor) beneficial differences between sarulimab and placebo. Phase III will continue with higher dose (400 mg) in critically ill patients.